ClinicalTrials.gg
TerminatedNCT00272987Updated Apr 28, 2023Results posted

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

A Phase 3 interventional study of lapatinib and paclitaxel in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Terminated at 16 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Enrollment was closed after the open label stage due to poor recruitment rate (randomized stage never opened).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
37th of 114
63 · median 35
Started
2005
with 8 others
Phase 3
18 of 114
none open now
Registered
16th of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 37th largest by enrollment, is one of 9 that started in 2005, is one of 18 in phase 3, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

This study was originally designed as a Phase III randomized, double blind, placebo controlled study to assess the safety and tolerability, and efficacy of paclitaxel plus trastuzumab plus lapatinib compared with paclitaxel plus trastuzumab plus placebo in women with ErbB2 overexpressing metastatic breast cancer. The planned study was a two stage design with an initial open-label safety stage to be conducted in approximately 65 subjects followed by a randomized phase conducted in a further 700 subjects. The open-label part of the study sequentially enrolled three cohorts with patients receiving a different dose combination of paclitaxel, trastuzumab and lapatinib. Following poor recruitment rate in the open label stage, the randomized stage of the study was terminated, thus no subjects were enrolled into the randomization stage.

Read the detailed description

The primary objective of this study was to evaluate and compare time to progression (TTP). The Primary objective for open label phase was to determine the safety and tolerability of lapatinib when administered in combination with both paclitaxel and trastuzumab. The study first enrolled an open label safety cohort of 20 patients to assess the tolerability of the triplet combination. This was a 1 arm, 3 cohort study stage.

Open-label Phase: Patients were sequentially enrolled into three cohorts and received an open-label combination of paclitaxel, trastuzumab and lapatinib: Cohort 1 received paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle, trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly, and lapatinib 1000 mg PO daily. Cohort 2 received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle, trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly, and lapatinib 1000 mg PO daily. Cohort 3 paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle, trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly, and lapatinib 750 mg PO daily.

Randomized Phase: was terminated following the poor recruitment rate in the open-label safety stage. No subjects were enrolled into the randomization stage.

In summary, at approximately 3.5 years the primary analysis which included demographics, efficacy and safety were conducted; at approximately 7 years protocol amendment 7 cancelled collection of efficacy endpoints, and only key safety endpoints were to be collected; the final analysis was performed at approximately 14 years.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • trastuzumab
  • ErbB2
  • paclitaxel
  • Herceptin
  • Taxol
  • ErbB1
  • metastatic breast cancer
  • Stage IV breast cancer
  • lapatinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive breast cancer with stage IV disease
  • If trastuzumab was administered in the setting, >12 months must have elapsed since discontinuation of trastuzumab therapy
  • If a taxane was administered in the neoadjuvant or adjuvant setting, progression must have occurred ≥12 months after completion of this treatment
  • Had tumors that overexpress ErbB2 defined as either: 3+ by IHC OR c-erbB2 gene amplification by FISH OR 0, 1+, 2+ by IHC and c-erbB2 gene amplification by FISH.
  • Patients must have tumor tissue available for central testing, and must have (s) according to
  • Subjects must be females of at least 18 years Non- or Childbearing potential but using adequate
  • Radiotherapy to a limited area other than the sole site of measurable and assessable disease is allowed; however, patients must have completed treatment and recovered from all acute treatment-related toxicities prior to administration of the first dose of study medication
  • Bisphosphonate therapy for bone is allowed; however, treatment must be initiated prior to the first dose of randomized therapy. Prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis
  • (ECOG) Performance Status 0 to 1
  • For those patients whose disease is estrogen receptor positive+ and/or progesterone receptor + one the following criteria should be met: Patients with visceral disease that requires chemotherapy (eg., patients with liver or lung metastases) or Rapidly progressing/life threatening disease, as determined by the investigator or Patients who received hormonal therapy and are no longer benefiting from this therapy;
  • Able to swallow and retain oral medication
  • Cardiac within institutional range of normal
  • Patient must have adequate organ function

Exclusion criteria

Exclusion criteria:

  • Pregnant or lactating females;
  • Received prior chemotherapy, immunotherapy, biologic therapy, or anti-ErbB1/ErbB2 therapy for disease, prior hormonal therapy is permitted but must be discontinued a minimum of 7 days prior to randomization;
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Patients with ulcerative colitis are also excluded;
  • History of other ; however, patients who have been disease-free for five years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
  • Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical disorder that would interfere with the patient's safety;
  • Unresolved or unstable, serious toxicity from prior administration of another drug and/or of prior cancer treatment;
  • Peripheral neuropathy of Grade 2 or greater;
  • Active or uncontrolled infection;
  • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of ;
  • Known history of uncontrolled or symptomatic angina, arrhythmias, conduction abnormalities or congestive heart failure;
  • Known history or clinical evidence of central nervous system (CNS) metastases or ;
  • Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy);
  • Concurrent treatment with an investigational agent or participation in another clinical trial;
  • Concurrent treatment with any medication on the prohibited medications list.
  • Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of treatment. Hormonal therapy needs to be discontinued at least 7 days before the first dose of treatment.
  • Prior therapy with an ErbB2 inhibitor, other than trastuzumab in the setting;
  • A known immediate or delayed reaction to drugs chemically related to lapatinib or ;
  • A known immediate or delayed hypersensitivity reaction to drugs chemically related to paclitaxel or excipients;
  • A known immediate or delayed hypersensitivity reaction to drugs chemically related to trastuzumab or excipients;
  • Non compliance with any of the screening procedures
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants received: paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily

    Drug: lapatinib · Drug: paclitaxel · Drug: trastuzumab

  • Experimental
    Cohort 2

    Participants received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily.

    Drug: lapatinib · Drug: paclitaxel · Drug: trastuzumab

  • Experimental
    Cohort 3

    Participants in this arm received 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 750 mg PO

    Drug: lapatinib · Drug: paclitaxel · Drug: trastuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Mean/Standard Deviation

    Extent of exposure is defined as the duration of the treatment administered during the study. The mean duration of exposure to lapatinib, trastuzumab and paclitaxel is calculated as the number of weeks between the start and end of treatment.

    Time frame: From the date of the first dose of the investigational product to end of study, up to approx. 14 years

  2. Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Median/Min-Max

    Extent of exposure is defined as the duration of the treatment administered during the study. The mean duration of exposure to lapatinib, trastuzumab and paclitaxel is calculated as the number of weeks between the start and end of treatment.

    Time frame: From the date of the first dose of the investigational product to end of study, up to approx. 14 years

  3. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general AE/SAE module for a list of non-serious AEs and SAEs.

    Time frame: From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 14 years

  4. Number of Participants Who Died Due to Any Cause

    Number of participants who died due to any cause throughout the study including off-treatment deaths (on-treatment deaths are reported for the All-Cause Mortality in the AE section).

    Time frame: From the date of the first dose of investigational product until last patient last visit, up to approximately 14 years

  5. Number of Events of Diarrhea With the Indicated Characteristics

    Events of diarrhea are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.

    Time frame: From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years

  6. Number of Events of Rash With the Indicated Characteristics

    Events of rash are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.

    Time frame: From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years

  7. Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Hematology Parameters

    Blood samples for clinical laboratory evaluation were taken at Baseline prior to the administration of investigational product and thereafter at each scheduled visit. Haematology parameters included haemoglobin, total white blood cell count (WBC), neutrophils, lymphocytes and platelets. Hematology data was summarized by the National Cancer Institute's Common toxicity criteria for adverse events (NCI CTCAE) toxicity grade (Version 3.0). Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death.

    Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years

  8. Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters

    Blood samples for clinical laboratory evaluation were taken at Baseline prior to the administration of investigational product and thereafter at each scheduled visit. Clinical chemistry parameters included values \> upper limit of normal (ULN)=Hyper; values \< lower limit of normal (LLN)=Hypo of sodium (Hypernatraemia and Hyponatraemia), potassium (Hyperkalaemia and Hypokalaemia), calcium (Hypercalcaemia and Hypocalcaemia), glucose (Hyperglycaemia and Hyperglycaemia), creatinine (if \>2 milligram per deciliter \[mg/dL\]), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phophatase, total bilirubin (if available bilirubin fractionation is recommended if the total bilirubin is \> twice of ULN), and albumin. Clinical chemistry data was summarized by National Cancer Institute's Common toxicity criteria for adverse events (NCI CTCAE) toxicity grade (Version 3.0). Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death.

    Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years

  9. Number of Events of Hepatotoxicity With the Indicated Characteristics

    Events of hepatotoxicity are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.

    Time frame: From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years

  10. Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at the Indicated Time Points

    Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years

  11. Change From Baseline in Heart Rate at the Indicated Time Points

    Heart rate was measured at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years

  12. Change From Baseline in Body Temperature at the Indicated Time Points

    Body temperature was measured at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years

  13. Number of Participants With at Least 1 Event of Left Ventricular Ejection Fraction Decrease With the Indicated Characteristics

    Events of left ventricular ejection fraction (LVEF) decrease were based on the number of participants who had an actual event and was characterized as serious, related to investigational product, leading to withdrawal from the study and/or fatal.

    Time frame: Baseline and every 8 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years

  14. Number of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status Value

    The Eastern Cooperative Oncology Group (ECOG) performance status scales and grades/criteria are used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the participant, and to determine appropriate treatment and prognosis. Grade 0, fully active, able to carry on all pre-disease performance without restriction. Grade 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. Grade 2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about more than 50% of waking hours. Grade 3, capable of only limited selfcare; confined to bed or chair more than 50% of waking hours. Grade 4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. Grade 5, dead.

    Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years

  15. Number of Participants Who Received Any Concomitant Medications During the Study Period

    Number of participants who received any concomitant medication along with study drugs (lapatinib, trastuzumab and paclitaxel) were counted during the treatment period.

    Time frame: withdrawal/study completion, up to approx. 3.5 years

  16. Overall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator

    OR is defined as the number of participants achieving either a CR or PR, per Response Evaluation Criteria in Solid Tumors (RECIST). The best OR is defined as the best response recorded from the start of treatment until progressive disease (PD)/recurrence. CR is defined as the disappearance of all target lesions (TLs) and non-TLs. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL(s), as assessed by the IRC. PD is defined as at least a 20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs. Responses were confirmed at subsequent assessments made \>=28 days after the original response. Participants with an unknown or missing response are treated as non-responders.

    Time frame: From the date of the first dose of investigational product to end of study, up to approx. 7 years

Secondary outcomes

  1. Time to Response as Assessed by the Investigator

    Time to Response was defined for subjects who had a confirmed CR or PR as the time from first dose until first documented evidence of partial or complete tumour response (whichever status was recorded first). CR is defined as the disappearance of all TLs \& non-TLs. PR is defined as at least a 30% decrease in the sum of the LD of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL(s). PD is defined as at least a 20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs.

    Time frame: From the date of the first dose of investigational product until the first documented evidence of a PR or CR, up to approx. 7 years

  2. Duration of Response (DoR), as Assessed by the Investigator

    DoR is defined for the subset of participants who had a confirmed CR (disappearance of all TLs and non-TLs) or PR (\>=30% decrease in the sum of the LD of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL\[s\]) as the time from the first documented evidence of a CR or PR until the first documentation of radiological PD or death due to breast cancer, if sooner. PD is defined as \>=20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs. For participants who did not progress or die, DoR was censored on the date of the last radiological scan. If a participant had only a Baseline visit or did not have a date of a radiological scan that was later than the date of initiation of anti-cancer therapy, DoR was censored at the start date of treatment.

    Time frame: From the first documented evidence of a PR or CR until the earlier of the date of disease progression or the date of death due to breast cancer, up to approx. 7 years

  3. Percentage of Participants With Clinical Benefit (Complete Response (CR), Partial Response (PR), and Stable Disease [SD] for at Least 24 Weeks) as Assessed by Investigator

    Clinical benefit is defined as the percentage of participants achieving either a CR or PR or SD (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of the LD of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions), taking as reference, the smallest sum LD since the treatment started) for at least 24 weeks. This was based on confirmed responses from the investigator assessment of clinical benefit.

    Time frame: From the date of the first dose of investigational product until the first documented evidence of a PR or CR or SD until the earlier of the date of disease progression or the date of death due to breast cancer, up to approx. 7 years

  4. Progression-free Survival as Assessed by the Investigator

    Progression-free survival is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. Disease progression was based on the investigator's assessments of the objective evidence (e.g., radiological scans and medical photographs). For participants who do not progress, or die, progression-free survival was censored at the time of the last investigator assessed radiological scan preceding the initiation of any alternative anti-cancer therapy. Progression-free survival was summarized using Kaplan-Meier curves.

    Time frame: From the date of the first dose of investigational product until the earlier of the date of disease progression or death due to any cause, up to approx. 7 years

07

Results

Posted Aug 20, 2014

Participant flow

Female participants (par.) with histologically confirmed invasive breast cancer (Stage IV disease) whose tumors overexpressed the ErbB2 protein, documented by either Immunohistochemistry (IHC) or fluorescence in situ hybridisation (FISH), were eligible for inclusion in this study.

Participant flow — Overall Study
MilestoneCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Started291420
Completed20109
Not completed9411
Withdrew: Adverse event100
Withdrew: Lost to follow-up311
Withdrew: Withdrawal by subject103
Withdrew: Sponsor terminated study011
Withdrew: Disease progression112
Withdrew: Non-compliant- study visits, trtmnts, req. surgery214
Withdrew: Death100

Outcome measures

PrimaryExtent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Mean/Standard Deviation

Extent of exposure is defined as the duration of the treatment administered during the study. The mean duration of exposure to lapatinib, trastuzumab and paclitaxel is calculated as the number of weeks between the start and end of treatment.

Time frame:
From the date of the first dose of the investigational product to end of study, up to approx. 14 years
Reported as:
Mean · Weeks
Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Mean/Standard Deviation
WeeksCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Lapatinib70.9 ± 115.4493.1 ± 147.9282.5 ± 135.79
Trastuzumab60.7 ± 72.0772.2 ± 88.6662.3 ± 75.52
Paclitaxel26.9 ± 16.8829.4 ± 23.0023.8 ± 14.87
PrimaryExtent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Median/Min-Max

Extent of exposure is defined as the duration of the treatment administered during the study. The mean duration of exposure to lapatinib, trastuzumab and paclitaxel is calculated as the number of weeks between the start and end of treatment.

Time frame:
From the date of the first dose of the investigational product to end of study, up to approx. 14 years
Reported as:
Median · Weeks
Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Median/Min-Max
WeeksCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Lapatinib33.0 (3 to 615)38.5 (2 to 547)32.5 (1 to 574)
Trastuzumab33.0 (2 to 343)37.0 (2 to 271)31.5 (1 to 245)
Paclitaxel22.0 (2 to 86)23.5 (2 to 94)22.0 (1 to 63)
PrimaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general AE/SAE module for a list of non-serious AEs and SAEs.

Time frame:
From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 14 years
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Any AEs291420
Any SAEs1465
PrimaryNumber of Participants Who Died Due to Any Cause

Number of participants who died due to any cause throughout the study including off-treatment deaths (on-treatment deaths are reported for the All-Cause Mortality in the AE section).

Time frame:
From the date of the first dose of investigational product until last patient last visit, up to approximately 14 years
Reported as:
Number · Participants
Number of Participants Who Died Due to Any Cause
ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Number of Participants Who Died Due to Any Cause1221
PrimaryNumber of Events of Diarrhea With the Indicated Characteristics

Events of diarrhea are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.

Time frame:
From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Reported as:
Number · Events of diarrhea
Number of Events of Diarrhea With the Indicated Characteristics
Events of diarrheaCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Any Event3589037
Serious400
Related to investigational product3477526
Leading to withdrawal from study211
Fatal000
PrimaryNumber of Events of Rash With the Indicated Characteristics

Events of rash are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.

Time frame:
From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Reported as:
Number · Events of rash
Number of Events of Rash With the Indicated Characteristics
Events of rashCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Any Event692320
Serious200
Related to investigational product55127
Leading to withdrawal from study300
Fatal000
PrimaryNumber of Participants With the Maximum Toxicity Grade for the Indicated Clinical Hematology Parameters

Blood samples for clinical laboratory evaluation were taken at Baseline prior to the administration of investigational product and thereafter at each scheduled visit. Haematology parameters included haemoglobin, total white blood cell count (WBC), neutrophils, lymphocytes and platelets. Hematology data was summarized by the National Cancer Institute's Common toxicity criteria for adverse events (NCI CTCAE) toxicity grade (Version 3.0). Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death.

Time frame:
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Reported as:
Number · Participants
Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Hematology Parameters
ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Haemaglobin, Grade 1191111
Haemaglobin, Grade 2716
Haemaglobin, Grade 3201
Haemaglobin, Grade 4100
Platelets, Grade 1300
Platelets, Grade 2100
Platelets, Grade 3000
Platelets, Grade 4100
Total WBC, Grade 11067
Total WBC, Grade 2842
Total WBC, Grade 3314
Total WBC, Grade 4100
Neutrophils, Grade 1725
Neutrophils, Grade 2744
Neutrophils, Grade 3315
Neutrophils, Grade 4300
Lymphocytes, Grade 1537
Lymphocytes, Grade 21044
Lymphocytes, Grade 3531
Lymphocytes, Grade 4101
PrimaryNumber of Participants With the Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters

Blood samples for clinical laboratory evaluation were taken at Baseline prior to the administration of investigational product and thereafter at each scheduled visit. Clinical chemistry parameters included values \> upper limit of normal (ULN)=Hyper; values \< lower limit of normal (LLN)=Hypo of sodium (Hypernatraemia and Hyponatraemia), potassium (Hyperkalaemia and Hypokalaemia), calcium (Hypercalcaemia and Hypocalcaemia), glucose (Hyperglycaemia and Hyperglycaemia), creatinine (if \>2 milligram per deciliter \[mg/dL\]), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phophatase, total bilirubin (if available bilirubin fractionation is recommended if the total bilirubin is \> twice of ULN), and albumin. Clinical chemistry data was summarized by National Cancer Institute's Common toxicity criteria for adverse events (NCI CTCAE) toxicity grade (Version 3.0). Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death.

Time frame:
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Reported as:
Number · Participants
Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters
ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Hypernatraemia, Grade 1011
Hypernatraemia, Grade 2100
Hypernatraemia, Grade 3000
Hypernatraemia, Grade 4000
Hyponatraemia, Grade 1811
Hyponatraemia, Grade 2000
Hyponatraemia, Grade 3010
Hyponatraemia, Grade 4000
Hyperkalaemia, Grade 1200
Hyperkalaemia, Grade 2211
Hyperkalaemia, Grade 3000
Hyperkalaemia, Grade 4101
Hypokalaemia, Grade 11166
Hypokalaemia, Grade 2000
Hypokalaemia, Grade 3620
Hypokalaemia, Grade 4000
Hypercalcaemia, Grade 1100
Hypercalcaemia, Grade 2000
Hypercalcaemia, Grade 3000
Hypercalcaemia, Grade 4000
Hypocalcaemia, Grade 11034
Hypocalcaemia, Grade 2723
Hypocalcaemia, Grade 3301
Hypocalcaemia, Grade 4000
Hyperglycaemia, Grade 11596
Hyperglycaemia, Grade 2332
Hyperglycaemia, Grade 3502
Hyperglycaemia, Grade 4000
Hypoglycemia, Grade 1522
Hypoglycemia, Grade 2011
Hypoglycemia, Grade 3000
Hypoglycemia, Grade 4000
Albumin, Grade 1531
Albumin, Grade 2300
Albumin, Grade 3100
Albumin, Grade 4000
Total Bilirubin, Grade 1213
Total Bilirubin, Grade 2221
Total Bilirubin, Grade 3110
Total Bilirubin, Grade 4000
Creatinine, Grade 1200
Creatinine, Grade 2200
Creatinine, Grade 3100
Creatinine, Grade 4000
Alkaline Phophatase, Grade 11435
Alkaline Phophatase, Grade 2200
Alkaline Phophatase, Grade 3200
Alkaline Phophatase, Grade 4000
ALT, Grade 1713
ALT, Grade 2332
ALT, Grade 3000
ALT, Grade 4000
AST, Grade 1636
AST, Grade 2110
AST, Grade 3110
AST, Grade 4000
PrimaryNumber of Events of Hepatotoxicity With the Indicated Characteristics

Events of hepatotoxicity are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.

Time frame:
From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Reported as:
Number · Events of hepatotoxicity
Number of Events of Hepatotoxicity With the Indicated Characteristics
Events of hepatotoxicityCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Any Event6—2
Serious0—0
Related to investigational product5—0
Leading to withdrawal from study0—0
Fatal0—0
PrimaryChange From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at the Indicated Time Points

Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Reported as:
Mean · Millimeter of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at the Indicated Time Points
Millimeter of mercury (mmHg)Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
SBP, Week 40.5 ± 16.29-7.2 ± 20.70-3.9 ± 22.76
SBP, Week 84.6 ± 12.35-8.6 ± 22.25-2.7 ± 24.73
SBP, Week 123.2 ± 18.46-6.9 ± 17.09-9.3 ± 23.54
SBP, Week 160.8 ± 18.10-6.6 ± 15.26-7.9 ± 24.43
SBP, Week 201.7 ± 17.80-11.5 ± 14.69-13.8 ± 25.15
SBP, Week 242.9 ± 13.87-1.8 ± 11.81-7.8 ± 26.06
SBP, Week 282.3 ± 19.10-5.7 ± 20.38-5.2 ± 10.71
SBP, Week 323.2 ± 23.11-16.4 ± 10.03-6.3 ± 5.51
SBP, Week 361.6 ± 15.85-8.7 ± 12.19-26.7 ± 37.75
SBP, Week 40-2.2 ± 24.44-3.4 ± 9.62-34.0 ± 38.18
SBP, Week 442.7 ± 14.47-3.8 ± 9.83-38.0 ± 32.53
SBP, Week 486.5 ± 18.76-6.7 ± 11.18-84.0 ± NA
SBP, Week 527.7 ± 14.47-3.8 ± 24.78—
SBP, Week 568.4 ± 13.53-8.2 ± 18.74—
SBP, Week 609.3 ± 22.07-17.0 ± 9.31—
SBP, Week 643.5 ± 16.53-11.3 ± 11.24—
SBP, Week 680.1 ± 10.71-6.5 ± 12.02—
SBP, Week 727.1 ± 13.25-20.0 ± NA—
SBP, Week 764.5 ± 12.96——
SBP, Week 808.7 ± 6.92——
SBP, Week 847.0 ± 20.20——
SBP, Week 88-2.7 ± 16.32——
SBP, Week 9210.4 ± 16.59——
SBP, Week 96-0.5 ± 4.12——
SBP, Week 10010.8 ± 7.53——
SBP, Week 1047.0 ± 16.00——
SBP, Week 1084.6 ± 7.89——
SBP, Week 11212.3 ± 10.72——
SBP, Week 1169.3 ± 15.22——
SBP, Week 12013.3 ± 19.86——
SBP, Week 1247.3 ± 8.50——
SBP, Week 128-11.0 ± 9.90——
SBP, Week 132-10.5 ± 10.61——
SBP, Week 136-4.0 ± 18.38——
SBP, Week 1404.5 ± 23.33——
SBP, Week 14410.0 ± 0——
SBP, Week 14825.0 ± NA——
SBP, Withdrawal/Study Conclusion0.5 ± 16.13-1.3 ± 15.647.0 ± 20.28
SBP, 30 Day Follow-up2.4 ± 19.18-3.9 ± 17.0313.8 ± 19.25
DBP, Week 4-2.5 ± 10.36-3.9 ± 10.50-4.8 ± 11.10
DBP, Week 8-0.6 ± 11.41-8.9 ± 11.54-1.2 ± 12.46
DBP, Week 12-0.3 ± 10.19-6.2 ± 10.37-4.2 ± 12.87
DBP, Week 16-3.4 ± 12.98-3.2 ± 8.42-4.4 ± 15.18
DBP, Week 20-3.0 ± 12.65-1.6 ± 9.53-9.1 ± 13.65
DBP, Week 24-1.2 ± 11.30-1.8 ± 6.56-5.2 ± 13.08
DBP, Week 28-1.8 ± 14.27-2.1 ± 8.15-2.0 ± 5.05
DBP, Week 32-2.2 ± 13.70-6.3 ± 10.24-4.7 ± 6.51
DBP, Week 36-7.2 ± 6.48-3.3 ± 6.40-10.7 ± 11.02
DBP, Week 40-9.3 ± 11.36-0.7 ± 13.76-8.0 ± 19.80
DBP, Week 44-9.0 ± 6.59-2.3 ± 10.33-19.5 ± 6.36
DBP, Week 48-3.9 ± 7.57-0.2 ± 8.13-34.0 ± NA
DBP, Week 52-7.4 ± 13.46-3.0 ± 12.33—
DBP, Week 56-5.1 ± 8.62-3.4 ± 7.99—
DBP, Week 60-3.6 ± 11.56-6.3 ± 6.24—
DBP, Week 64-7.7 ± 12.27-5.3 ± 8.54—
DBP, Week 68-11.0 ± 6.40-3.5 ± 7.78—
DBP, Week 723.0 ± 9.26-16.0 ± NA—
DBP, Week 76-4.8 ± 5.00——
DBP, Week 80-3.5 ± 5.58——
DBP, Week 84-5.8 ± 9.50——
DBP, Week 88-9.3 ± 11.48——
DBP, Week 92-3.8 ± 5.26——
DBP, Week 96-7.3 ± 6.29——
DBP, Week 100-4.4 ± 6.50——
DBP, Week 104-4.6 ± 9.10——
DBP, Week 108-2.0 ± 5.89——
DBP, Week 116-8.5 ± 9.33——
DBP, Week 120-6.0 ± 7.94——
DBP, Week 124-6.0 ± 6.00——
DBP, Week 128-12.5 ± 0.71——
DBP, Week 132-14.5 ± 4.95——
DBP, Week 136-17.0 ± 4.24——
DBP, Week 140-7.5 ± 10.61——
DBP, Week 1440.0 ± 0——
DBP, Week 1481.0 ± NA——
DBP, Withdrawal/Study Conclusion-0.5 ± 11.39-0.4 ± 12.082.1 ± 8.64
DBP, 30 Day Follow-up-0.8 ± 11.960.8 ± 11.623.2 ± 9.98
PrimaryChange From Baseline in Heart Rate at the Indicated Time Points

Heart rate was measured at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Reported as:
Mean · Beats per minute (BPM)
Change From Baseline in Heart Rate at the Indicated Time Points
Beats per minute (BPM)Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Week 4-1.714 ± 10.9099-3.417 ± 26.35933.333 ± 12.1268
Week 8-5.667 ± 14.7908-3.231 ± 16.84815.353 ± 10.7642
Week 12-0.217 ± 10.7109-0.417 ± 15.6812-2.875 ± 10.6074
Week 16-0.478 ± 13.46672.625 ± 15.1369-1.917 ± 10.9084
Week 24-0.476 ± 16.7768-5.300 ± 15.18085.167 ± 10.2843
Week 28-4.313 ± 16.0155-1.429 ± 17.72813.600 ± 8.5615
Week 32-4.933 ± 16.6496-0.500 ± 11.10980.333 ± 10.5987
Week 36-5.000 ± 13.01284.857 ± 18.47917.000 ± 11.5326
Week 40-1.000 ± 14.1614-3.571 ± 17.6149-2.500 ± 9.1924
Week 44-3.000 ± 11.1624-5.000 ± 17.9778-0.500 ± 10.6066
Week 48-5.500 ± 8.1955-2.500 ± 12.9422-14.000 ± NA
Week 52-1.889 ± 14.4866-2.000 ± 11.8533—
Week 56-2.000 ± 13.4907-2.000 ± 15.2151—
Week 60-2.600 ± 13.37661.500 ± 15.0222—
Week 64-4.667 ± 16.12450.000 ± 15.3840—
Week 68-8.286 ± 21.16381.000 ± 25.4558—
Week 72-0.714 ± 21.029519.000 ± NA—
Week 76-0.500 ± 16.6463——
Week 800.800 ± 14.4810——
Week 849.200 ± 21.1234——
Week 882.200 ± 24.6110——
Week 92-2.400 ± 10.1390——
Week 96-8.250 ± 7.6322——
Week 100-6.750 ± 13.1751——
Week 104-6.800 ± 15.3525——
Week 108-8.750 ± 6.4485——
Week 112-0.667 ± 15.0444——
Week 116-4.667 ± 14.5717——
Week 120-7.667 ± 9.4516——
Week 124-5.333 ± 13.2035——
Week 1281.000 ± 21.2132——
Week 132-4.000 ± 14.1421——
Week 136-4.000 ± 15.5563——
Week 140-3.500 ± 16.2635——
Week 1443.000 ± NA——
Week 1486.000 ± NA——
Withdrawal/Study Conclusion-1.435 ± 19.3481-7.900 ± 19.39907.750 ± 9.8814
30 Day Follow-up0.560 ± 13.1564-7.889 ± 17.352613.200 ± 11.6060
PrimaryChange From Baseline in Body Temperature at the Indicated Time Points

Body temperature was measured at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Reported as:
Mean · Degree Celsius
Change From Baseline in Body Temperature at the Indicated Time Points
Degree CelsiusCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Week 4-0.229 ± 0.5062-0.242 ± 0.36050.078 ± 0.5976
Week 80.011 ± 0.5250-0.154 ± 0.42940.247 ± 0.4652
Week 120.021 ± 0.4374-0.567 ± 0.49600.173 ± 0.4636
Week 16-0.052 ± 0.5814-0.127 ± 0.48800.121 ± 0.5494
Week 200.018 ± 0.5712-0.238 ± 0.41380.300 ± 0.3536
Week 240.157 ± 0.5006-0.100 ± 0.41380.017 ± 0.5193
Week 28-0.094 ± 0.4956-0.529 ± 0.47510.300 ± 0.3536
Week 32-0.156 ± 0.6077-0.237 ± 0.21340.000 ± 0.2000
Week 36-0.215 ± 0.5728-0.129 ± 0.39460.533 ± 0.3786
Week 400.045 ± 0.4634-0.314 ± 0.19520.450 ± 0.9192
Week 44-0.182 ± 0.4729-0.217 ± 0.39200.250 ± 0.0707
Week 48-0.109 ± 0.4571-0.200 ± 0.14140.300 ± NA
Week 52-0.222 ± 1.0616-0.340 ± 0.3286—
Week 560.111 ± 0.6489-0.240 ± 0.6427—
Week 60-0.070 ± 0.5889-0.225 ± 0.2754—
Week 64-0.080 ± 0.4662-0.150 ± 0.1732—
Week 680.286 ± 0.6744-0.550 ± 0.0707—
Week 720.057 ± 0.7390-0.400 ± NA—
Week 760.017 ± 0.4834——
Week 80-0.150 ± 0.6442——
Week 840.067 ± 0.5610——
Week 88-0.267 ± 0.4131——
Week 92-0.200 ± 0.8155——
Week 96-0.125 ± 0.4573——
Week 100-0.100 ± 0.9083——
Week 104-0.160 ± 0.7436——
Week 1080.080 ± 0.6099——
Week 1120.050 ± 0.5000——
Week 1160.250 ± 0.6403——
Week 1200.200 ± 0.4359——
Week 1240.167 ± 0.8083——
Week 1280.200 ± 1.4142——
Week 132-0.150 ± 1.2021——
Week 1360.000 ± 1.2728——
Week 1400.450 ± 1.3435——
Week 1441.300 ± NA——
Week 1480.700 ± NA——
Withdrawal/Study Conclusion-0.083 ± 0.6833-0.020 ± 0.43670.237 ± 0.5999
30 Day Follow-up-0.092 ± 0.6238-0.400 ± 0.50740.140 ± 0.5320
PrimaryNumber of Participants With at Least 1 Event of Left Ventricular Ejection Fraction Decrease With the Indicated Characteristics

Events of left ventricular ejection fraction (LVEF) decrease were based on the number of participants who had an actual event and was characterized as serious, related to investigational product, leading to withdrawal from the study and/or fatal.

Time frame:
Baseline and every 8 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Reported as:
Number · Participants
Number of Participants With at Least 1 Event of Left Ventricular Ejection Fraction Decrease With the Indicated Characteristics
ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Number of Participants With at Least 1 Event of Left Ventricular Ejection Fraction Decrease With the Indicated Characteristics820
PrimaryNumber of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status Value

The Eastern Cooperative Oncology Group (ECOG) performance status scales and grades/criteria are used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the participant, and to determine appropriate treatment and prognosis. Grade 0, fully active, able to carry on all pre-disease performance without restriction. Grade 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. Grade 2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about more than 50% of waking hours. Grade 3, capable of only limited selfcare; confined to bed or chair more than 50% of waking hours. Grade 4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. Grade 5, dead.

Time frame:
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Reported as:
Number · Participants
Number of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status Value
ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Screening, Grade 3000
Screening, Grade 4000
Screening, Grade 5000
Day 1 pre-dose, Grade 3000
Day 1 pre-dose, Grade 4000
Day 1 pre-dose, Grade 5000
Week 4, Grade 3000
Week 4, Grade 4000
Week 4, Grade 5000
Week 8, Grade 3000
Week 8, Grade 4000
Week 8, Grade 5000
Week 12, Grade 3000
Week 12, Grade 4000
Week 12, Grade 5000
Week 16, Grade 3000
Week 16, Grade 4000
Week 16, Grade 5000
Week 20, Grade 3000
Week 20, Grade 4000
Week 20, Grade 5000
Week 24, Grade 3000
Week 24, Grade 4000
Week 24, Grade 5000
Week 28, Grade 3000
Week 28, Grade 4000
Week 28, Grade 5000
Week 32, Grade 3000
Week 32, Grade 4000
Week 32, Grade 5000
Week 36, Grade 3000
Week 36, Grade 4000
Week 36, Grade 5000
Week 40, Grade 3000
Week 40, Grade 4000
Week 40, Grade 5000
Week 44, Grade 3000
Week 44, Grade 4000
Week 44, Grade 5000
Week 48, Grade 3000
Week 48, Grade 4000
Week 48, Grade 5000
Week 52, Grade300—
Week 52, Grade400—
Week 52, Grade500—
Week 56, Grade 300—
Week 56, Grade 400—
Week 56, Grade 500—
Week 60, Grade 300—
Week 60, Grade 400—
Week 60, Grade 500—
Week 64, Grade 300—
Week 64, Grade 400—
Week 64, Grade 500—
Week 68, Grade300—
Week 68, Grade400—
Week 68, Grade500—
Week 72, Grade 300—
Week 72, Grade 400—
Week 72, Grade 500—
Week 76, Grade30——
Week 76, Grade40——
Week 76, Grade50——
Week 80, Grade 30——
Week 80, Grade 40——
Week 80, Grade 50——
Week 84, Grade 30——
Week 84, Grade 40——
Week 84, Grade 50——
Week 88, Grade 30——
Week 88, Grade 40——
Week 88, Grade 50——
Week 92, Grade 30——
Week 92, Grade 40——
Week 92, Grade 50——
Week 96, Grade 30——
Week 96, Grade 40——
Week 96, Grade 50——
Week 100, Grade 30——
Week 100, Grade 40——
Week 100, Grade 50——
Week 104, Grade 30——
Week 104, Grade 40——
Week 104, Grade 50——
Week 108, Grade 30——
Week 108, Grade 40——
Week 108, Grade 50——
Week 112, Grade 30——
Week 112, Grade 40——
Week 112, Grade 50——
Week 116, Grade 30——
Week 116, Grade 40——
Week 116, Grade 50——
Week 120, Grade 30——
Week 120, Grade 40——
Week 120, Grade 50——
Week 124, Grade 30——
Week 124, Grade 40——
Week 124, Grade 50——
Week 128, Grade 30——
Week 128, Grade 40——
Week 128, Grade 50——
Week 132, Grade 30——
Week 132, Grade 40——
Week 132, Grade 50——
Week 136, Grade 30——
Week 136, Grade 40——
Week 136, Grade 50——
Week 140, Grade 32——
Week 140, Grade 40——
Week 140, Grade 50——
Week 144, Grade 30——
Week 144, Grade 40——
Week 144, Grade 50——
Week 148, Grade 30——
Week 148, Grade 40——
Week 148, Grade 50——
Withdrawal/Study conclusion, Grade 3000
Withdrawal/Study conclusion, Grade 4000
Withdrawal/Study conclusion, Grade 5000
PrimaryNumber of Participants Who Received Any Concomitant Medications During the Study Period

Number of participants who received any concomitant medication along with study drugs (lapatinib, trastuzumab and paclitaxel) were counted during the treatment period.

Time frame:
withdrawal/study completion, up to approx. 3.5 years
Reported as:
Number · Participants
Number of Participants Who Received Any Concomitant Medications During the Study Period
ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Number of Participants Who Received Any Concomitant Medications During the Study Period291420
PrimaryOverall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator

OR is defined as the number of participants achieving either a CR or PR, per Response Evaluation Criteria in Solid Tumors (RECIST). The best OR is defined as the best response recorded from the start of treatment until progressive disease (PD)/recurrence. CR is defined as the disappearance of all target lesions (TLs) and non-TLs. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL(s), as assessed by the IRC. PD is defined as at least a 20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs. Responses were confirmed at subsequent assessments made \>=28 days after the original response. Participants with an unknown or missing response are treated as non-responders.

Time frame:
From the date of the first dose of investigational product to end of study, up to approx. 7 years
Reported as:
Number · Percentage of participants
Overall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator
Percentage of participantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Overall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator79.3 (64.6 to 94.1)71.4 (47.8 to 95.1)70.0 (49.9 to 90.1)
SecondaryTime to Response as Assessed by the Investigator

Time to Response was defined for subjects who had a confirmed CR or PR as the time from first dose until first documented evidence of partial or complete tumour response (whichever status was recorded first). CR is defined as the disappearance of all TLs \& non-TLs. PR is defined as at least a 30% decrease in the sum of the LD of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL(s). PD is defined as at least a 20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs.

Time frame:
From the date of the first dose of investigational product until the first documented evidence of a PR or CR, up to approx. 7 years
Reported as:
Number · Participants
Time to Response as Assessed by the Investigator
ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Week 81588
Week 12511
Week 16213
Week 20001
Week 24100
Week 28001
SecondaryDuration of Response (DoR), as Assessed by the Investigator

DoR is defined for the subset of participants who had a confirmed CR (disappearance of all TLs and non-TLs) or PR (\>=30% decrease in the sum of the LD of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL\[s\]) as the time from the first documented evidence of a CR or PR until the first documentation of radiological PD or death due to breast cancer, if sooner. PD is defined as \>=20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs. For participants who did not progress or die, DoR was censored on the date of the last radiological scan. If a participant had only a Baseline visit or did not have a date of a radiological scan that was later than the date of initiation of anti-cancer therapy, DoR was censored at the start date of treatment.

Time frame:
From the first documented evidence of a PR or CR until the earlier of the date of disease progression or the date of death due to breast cancer, up to approx. 7 years
Reported as:
Median · Weeks
Duration of Response (DoR), as Assessed by the Investigator
WeeksCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Duration of Response (DoR), as Assessed by the Investigator56.6 (27.6 to 117.7)59.0 (33.1 to 88.7)70.6 (31.4 to 103.1)
SecondaryPercentage of Participants With Clinical Benefit (Complete Response (CR), Partial Response (PR), and Stable Disease [SD] for at Least 24 Weeks) as Assessed by Investigator

Clinical benefit is defined as the percentage of participants achieving either a CR or PR or SD (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of the LD of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions), taking as reference, the smallest sum LD since the treatment started) for at least 24 weeks. This was based on confirmed responses from the investigator assessment of clinical benefit.

Time frame:
From the date of the first dose of investigational product until the first documented evidence of a PR or CR or SD until the earlier of the date of disease progression or the date of death due to breast cancer, up to approx. 7 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Benefit (Complete Response (CR), Partial Response (PR), and Stable Disease [SD] for at Least 24 Weeks) as Assessed by Investigator
Percentage of ParticipantsCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Percentage of Participants With Clinical Benefit (Complete Response (CR), Partial Response (PR), and Stable Disease [SD] for at Least 24 Weeks) as Assessed by Investigator79.3 (64.6 to 94.1)71.4 (47.8 to 95.1)70.0 (49.9 to 90.1)
SecondaryProgression-free Survival as Assessed by the Investigator

Progression-free survival is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. Disease progression was based on the investigator's assessments of the objective evidence (e.g., radiological scans and medical photographs). For participants who do not progress, or die, progression-free survival was censored at the time of the last investigator assessed radiological scan preceding the initiation of any alternative anti-cancer therapy. Progression-free survival was summarized using Kaplan-Meier curves.

Time frame:
From the date of the first dose of investigational product until the earlier of the date of disease progression or death due to any cause, up to approx. 7 years
Reported as:
Median · Weeks
Progression-free Survival as Assessed by the Investigator
WeeksCohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
Progression-free Survival as Assessed by the Investigator64.7 (33.1 to 117)55.0 (20.4 to 96.1)78.4 (31.9 to 111)

Adverse events

Collected over Adverse Events (AEs) and Serious adverse events (SAEs) were collected from the first dose of investigational product to 30 days after the last dose of investigational product, up to approx.12 years (maximum exposure to Lapatinib (615 weeks) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Paclitaxel 80mg/Trastuzumab 4 mg/Lapatinib 1000mg0/29 (0%)14/29 (48.3%)29/29 (100%)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0/14 (0%)6/14 (42.9%)13/14 (92.9%)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0/20 (0%)5/20 (25%)20/20 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCohort 1: Paclitaxel 80mg/Trastuzumab 4 mg/Lapatinib 1000mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
DehydrationMetabolism and nutrition disorders5/290/141/20
CellulitisInfections and infestations0/292/140/20
Left ventricular dysfunctionCardiac disorders2/291/140/20
DiarrhoeaGastrointestinal disorders2/291/140/20
Drug hypersensitivityImmune system disorders0/291/140/20
PneumoniaInfections and infestations0/291/141/20
Ejection fraction decreasedInvestigations2/291/140/20
Pleural effusionRespiratory, thoracic and mediastinal disorders0/291/141/20
NeutropeniaBlood and lymphatic system disorders2/290/140/20
HypokalaemiaMetabolism and nutrition disorders2/290/140/20
Most frequent other events
Showing 10 of 163
Most frequent other events
EventCohort 1: Paclitaxel 80mg/Trastuzumab 4 mg/Lapatinib 1000mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg
DiarrhoeaGastrointestinal disorders28/2913/1415/20
RashSkin and subcutaneous tissue disorders25/299/1417/20
FatigueGeneral disorders21/2912/1413/20
NauseaGastrointestinal disorders16/2911/1413/20
AlopeciaSkin and subcutaneous tissue disorders22/298/1411/20
VomitingGastrointestinal disorders17/296/144/20
ConstipationGastrointestinal disorders7/297/145/20
InsomniaPsychiatric disorders6/297/143/20
Mucosal inflammationGeneral disorders8/296/142/20
Upper respiratory tract infectionInfections and infestations8/296/143/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mgTotal
Mean51.5 ± 11.0856.1 ± 11.9252.2 ± 13.0052.7 ± 11.84
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mgTotal
Female29142063
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mgCohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mgTotal
African American/African Heritage72413
Native Hawaiian or Other Pacific Islander0101
White - White/Caucasian/European Heritage22111649
08

Study locations

16 sites
  • Novartis Investigative Site
    Roswell, Georgia 30076, United States
  • Novartis Investigative Site
    Joliet, Illinois 60435, United States
  • Novartis Investigative Site
    Detroit, Michigan 48202, United States
  • Novartis Investigative Site
    Jackson, Mississippi 39202, United States
  • Novartis Investigative Site
    Voorhees, New Jersey 08043, United States
  • Novartis Investigative Site
    Winston-Salem, North Carolina 27103, United States
  • Novartis Investigative Site
    Canton, Ohio 44718, United States
  • Novartis Investigative Site
    Columbus, Ohio 43219, United States
  • Novartis Investigative Site
    Middletown, Ohio 45042, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29406, United States
  • Novartis Investigative Site
    Amarillo, Texas 79106, United States
  • Novartis Investigative Site
    Houston, Texas 77030-4009, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Richmond, Virginia 23230, United States
  • Novartis Investigative Site
    Arlon, 6700, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
09

References and documents

Publications

  • Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, Florance AM, Turner S, Stein S, Perez A. An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist. 2013 Jun;18(6):661-6. doi: 10.1634/theoncologist.2012-0129. Epub 2013 May 22. PubMed 23697602 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2005 to primary completion in Jul 2009, 43 months.

Results were first posted in Aug 2014, 5 years after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2006
First posted
Jan 9, 2006
StartActual
Dec 13, 2005
Primary completionActual
Jul 31, 2009
CompletionActual
Oct 21, 2019
Results delay requested
Aug 12, 2010
Results first posted
Aug 20, 2014
Last update
Apr 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00272987
Responsible party
Sponsor
First posted
Jan 9, 2006
Start date
Dec 13, 2005
Primary completion
Jul 31, 2009
Completion
Oct 21, 2019
Results posted
Aug 20, 2014
Last update
Apr 28, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Paclitaxel

Start the discussion